In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Evotec Drug Development Strategy Offers Little Downside, Big Upside

Executive Summary

Germany’s Evotec hopes to evolve into an integrated multi-service biopharma company through its three-pronged business strategy comprising a high-growth drug-discovery business, a series of pipeline options that pose no financial obligation for the biotech, and a growing list of scientific collaborations that offer potential long-term value.

You may also be interested in...



Verseon Claims Major Move In Drug Design, Will Enter Clinic Within A Year

The Fremont, California-based company has developed a computer-driven discovery platform that can model drug-protein interactions with unparalleled accuracy but can also generate synthetic pathways for its drug candidates.

Evotec Expands Sanofi Link With Exclusive Stem Cell Diabetes Deal

Evotec’s deal with the French drugmaker to develop stem cell-based treatments for diabetes takes on even more importance following the demise of the biotech’s two lead proprietary candidate therapies.

Evotec CEO: Growth Prospects Rely Heavily On Roche, Sanofi Deals

After disappearance last year of its drug hope DiaPep277 due to fraud, Germany’s Evotec is now looking to its Alzheimer’s MAO partnership with Roche and newly entered R&D alliance with Sanofi for future growth.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC143384

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel